

FOR IMMEDIATE RELEASE

HELIOS LISTS T2S GROUP ON THE CASABLANCA STOCK EXCHANGE

London / Casablanca, 27 July 2026 – Helios Investment Partners ("Helios"), the leading Africa-focused private investment firm, is pleased to announce the initial public offering of its portfolio company T2S Group Holding ("T2S Group" or the "Group") on the Casablanca Stock Exchange ("CSE"). The offering, of MAD 1.1 billion (c.USD 120 million), is one of the largest listings on the CSE in recent years and values the Group at a post-money market capitalisation of c.MAD 4.9 billion (c.USD 520 million) at listing.

The offering was 44 times oversubscribed, attracting strong demand from Moroccan and international investors. The capital raise provides liquidity to existing investors and supports the Group's continued growth. Helios remains T2S's largest shareholder, with a 42% stake post-IPO.

With more than 30 years of operating history, T2S Group is a leading integrated MedTech group serving public and private healthcare providers in Morocco and across Africa. The Group distributes, installs and maintains high-tech medical equipment and solutions, supporting the care pathway from diagnosis through treatment and throughout the equipment lifecycle. Across seven complementary business segments, T2S combines distribution, manufacturing, digital systems and technical services on behalf of blue-chip global manufacturers.

Helios' investment in the Group in 2021 allowed the integration of four complementary businesses, creating the leading integrated MedTech platform in the region. Working alongside founder Abderraouf Sordo and the management team, Helios strengthened the Group's governance and leadership and broadened management ownership. It also invested in T2S's operations, technology and commercial capabilities, building an integrated, service-led offering underpinned by recurring maintenance revenues and sustained expansion across the continent. These initiatives have established T2S as the leading medical equipment distribution and maintenance platform in francophone Africa and positioned the Group for continued growth.

Beyond its commercial success, T2S plays an important role in expanding access to advanced healthcare across its markets. The Group's development has accompanied Morocco's generalisation of universal health coverage and the modernisation of public and private healthcare infrastructure, while its investment in radiopharmaceutical production capacity and the training of local engineers and technicians is strengthening the healthcare ecosystems in which it operates.

Raed Barkatis, Head of Consumer non-discretionary sector at Helios Investment Partners, said: "It has been a privilege to work alongside Mr Sordo and the entire T2S team to build the leading integrated MedTech platform in Morocco. T2S has been a pioneer in introducing advanced medical technologies across Morocco and the wider African continent, helping

healthcare providers deliver the highest standards of patient care. Today's listing marks a significant milestone for the Group and opens an exciting new chapter in its development. We look forward to continuing to support T2S as it embarks on this next phase of growth."

Zineb Abbad El Andaloussi, Advisor at Helios Investment Partners, commented: "The quality of the T2S management team has been the driving force behind the Group's success. Their ability to execute and earn the trust of partners and healthcare providers across the region has been remarkable to witness. We are excited to continue supporting T2S Group in its mission in improving healthcare services across the region."

Abderraouf Sordo, Founder and Chief Executive Officer of T2S, added: "This listing is the culmination of more than thirty years of work by the T2S teams in the service of healthcare providers and patients. With Helios' backing over the past five years, we have built an integrated platform that is unique in our markets. Joining the Casablanca Stock Exchange gives us the means and the visibility to accelerate our development in Morocco and across Africa, and I am proud to open this new chapter alongside our employees, partners and new shareholders."

- ENDS -

For further information please contact:

Teneo
heliosmedia@teneo.com
+44 207 260 2700

About Helios Investment Partners

Established in 2004, Helios Investment Partners is the largest Africa-focused private investment firm, with a record that spans creating start-ups to providing expanding companies with growth capital and expertise. The firm is led and managed by a predominantly African team based in London, Paris, Lagos and Nairobi, with the language skills and cultural affinity to engage with local entrepreneurs, managers and intermediaries on the continent. Helios leverages its local and global networks to create attractive proprietary investment opportunities, with an emphasis on building market leaders in core economic sectors and driving performance through a highly engaged approach to portfolio operations. The firm's unique combination of a deep knowledge of the African operating environment, a singular commitment to the region and a proven capability to manage complexity, is reflected in its diverse portfolio of growing, market-leading businesses and its position as a partner of choice in Africa. Helios is the second mainstream private equity firm globally, and the largest emerging markets-focused private equity firm, to receive B Corp certification. B Corp status recognizes the firm's long-standing commitment to sustainability and responsible business practices.

Important Legal Information

This announcement is for information purposes only and does not constitute a prospectus or an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction. The prospectus approved by the Autorité Marocaine du Marché des Capitaux (AMMC) in connection with the initial public offering of T2S Group Holding is available on the websites of the issuer, the AMMC and the Casablanca Stock Exchange. This announcement may include forward-looking statements, which reflect current views with respect to future events and are subject to risks and uncertainties; actual results may differ materially.